Skip to content
Comparison

Ipamorelin vs Tesamorelin

Ipamorelin and Tesamorelin are commonly compared for general GH support versus visceral-fat targeted GH analog. Ipamorelin is usually favored for clean secretagogue profile for broader use cases, while Tesamorelin is often preferred for visceral-fat outcomes with approved clinical history. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For general GH support versus visceral-fat targeted GH analog, the better choice depends on your primary endpoint. Ipamorelin is stronger when the priority is general GH optimization with tolerability focus. Tesamorelin is stronger when the priority is visceral adiposity-targeted medically supervised plans. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaIpamorelinTesamorelin
Primary mechanismSelective GHS-R1a agonist (GHRP) with lower cortisol/prolactin signalFDA-approved GHRH analog for HIV lipodystrophy
Strongest clinical signalReliable GH pulse support with cleaner endocrine profile than older GHRPsStrong visceral-fat reduction in indicated populations
Typical dosing context100-300 mcg, often 1-3 times daily2 mg daily in approved protocol
AdministrationSubcutaneous injectionSubcutaneous injection
Evidence quality gradeModerate mechanistic and clinical supportStrong in HIV-lipodystrophy; moderate extrapolation outside indication
Regulatory statusNot FDA-approved; clinic/research useFDA-approved for HIV-associated lipodystrophy
Side-effect burdenGenerally mild side effects when appropriately dosedMonitor glucose tolerance and IGF-1 trends
Cost/access contextVariable clinic and compounding pricingHigh branded and clinic cost
Best candidate profileUsers seeking GH support with fewer appetite/cortisol issuesVisceral-adiposity endpoints with clinical supervision
Main limitationEvidence depth below approved endocrine therapiesExpensive and indication-specific evidence concentration
Best use case in this comparisongeneral GH optimization with tolerability focusvisceral adiposity-targeted medically supervised plans

When to Choose Each

Choose Ipamorelin

Best for general GH optimization with tolerability focus.

Choose Tesamorelin

Best for visceral adiposity-targeted medically supervised plans.

Verdict

If the main goal is general GH optimization with tolerability focus, Ipamorelin is usually the better first-line choice. If the main goal is visceral adiposity-targeted medically supervised plans, Tesamorelin is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Ipamorelin, the first selective growth hormone secretagogue (1998) — PubMed
  2. Ghrelin is a growth-hormone-releasing acylated peptide from stomach (1999) — PubMed
  3. A synthetic fragment of human growth hormone (AOD9604) that reduces body fat in obese Zucker rats (2001) — PubMed
  4. Comparative effects of growth hormone secretagogues on GH, cortisol, and prolactin release in humans (2005) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for general GH support versus visceral-fat targeted GH analog — Ipamorelin or Tesamorelin?
Ipamorelin is graded as moderate mechanistic and clinical support evidence in this context, while Tesamorelin is graded as strong in hiv-lipodystrophy; moderate extrapolation outside indication. In practice, strength depends on whether you prioritize general GH optimization with tolerability focus or visceral adiposity-targeted medically supervised plans. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Ipamorelin and Tesamorelin be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next